Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: GlobalData
|
$125.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: GlobalData
|
$250.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ambu A/S Issues FY 2012/2013 Financial Guidance Below Analysts' Estimates; Proposes FY 2011/2012 Dividend of DKK 3.00 per Share
Ambu A/S announced its fiscal year 2012/2013 financial guidance. The Company expects to report fiscal year 2012/2013 consolidated revenue to increase to approximately DKK 1,125 million, corresponding to an increase of approximately between 7% and 8% when reported in local currencies, including the full year effect of the acquired electrode business. The Company also expects to report fiscal year 2012/2013 EBIT margin before special items of approximately 15% while fiscal year 2012/2013 profit before special items and tax is expected to equate to approximately 14.5% of revenue. The Company also expects to report fiscal year 2012/2013 free cash flow before acquisitions of approximately DKK 100 million with investments before acquisitions amounting to approximately 5% of revenue. According to I/B/E/S estimates, analysts on average are expecting the Company to report fiscal year 2012/2013 revenue of DKK 1,109.29 million and fiscal year 2012/2013 pre-tax profit of DKK 170.10 million. The Company also announced that its Board of Directors has proposed a dividend be declared of DKK 3.00 per share for fiscal year 2011/2012. The proposed dividend payment date is December 19, 2012. For fiscal year 2010/2011, the Company paid a dividend of DKK 2.00 per share.
Latest Developments for Ambu A/S
- Ambu A/S Acquires First Water Heathcote Ltd in United Kingdom
- Ambu A/S Maintains FY 2012/2013 Revenue Guidance and Lowers FY 2012/2013 EBITDA Margin and EBIT Margin Outlook
- Ambu A/S Finalizes Acquisition of King Systems Inc.
- Consort Medical Plc Announces Proposed Disposal Of King Systems Corporation To Ambu A/S
Latest Key Developments in Medical
- CryoLife Inc Receives Conditional IDE Approval To Begin Clinical Trials For PerClot In The U.S.
- Essilor International SA Acquires Eight Businesses
- MIT Capital Inc Proposes To Acquire Meade Instruments Corp For $3.65 Per Share In Cash
- FDA Grants Prostate IDE Approval For Angiodynamics Inc's NanoKnife System
- Share this
- Link this
- Digg this


Follow Reuters